Subscribe
Sal Anastasi, new AIPLA president and partner at Barley Snyder
6 November 2025NewsAmericasSarah Speight

New AIPLA president calls for greater certainty in US patent law

Barley Snyder partner Sal Anastasi—woodworker, pilot, and now head of the AIPLA—speaks to WIPR about the urgent need for clarity in patent eligibility, and why collaboration and engagement are essential as the USPTO ushers in a period of rapid change.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025   In his first public remarks since becoming the USPTO director, a bombastic John Squires promises an agency “in overdrive” that's doubling down on AI, reports Sarah Speight.
Americas
Delegates descend upon Washington, DC for AIPLA Annual Meeting
30 October 2025   Private practitioners, in-house counsel and IP services from around the world converge in the US capital for the major event, from where Sarah Speight provides on-the-ground coverage.


Editor's picks

Regeneron and CureVac: UPC ‘cannot be ignored’
Unified Patent Court
Regeneron and CureVac: UPC ‘cannot be ignored’
4 November 2025

Editor's picks

Unified Patent Court
Regeneron and CureVac: UPC ‘cannot be ignored’
4 November 2025
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025

More features

Pfizer can’t block Novo Nordisk’s $10bn takeover deal
Regeneron and CureVac: UPC ‘cannot be ignored’
US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Is Hatch-Waxman litigation for orphan drugs working?
Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer